Bolt Biotherapeutics Q3 collaboration revenue doubles

Bolt Biotherapeutics

12/11/2025 21:38

Overview

Bolt Biotherapeutics Q3 collaboration revenue rises to $2.2 mln, doubling from last year

Company's net loss for Q3 narrows significantly compared to the same period last year

Cash balance of $38.8 mln expected to fund operations into 2027

Outlook

Company anticipates cash balance to fund operations into 2027

Bolt seeks partner for further development of BDC-3042

Result Drivers

R&D expenses were $6.5 million for the quarter ended September 30, 2025, compared to $13.8 million for the same quarter in 2024

STEP-UP DOSING - Co modified BDC-4182 trial protocol for step-up dosing after strong immune response at initial dose levels

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$2.17 mln
Q3 Net Income
-$7.14 mln
Q3 Basic EPS
-$3.72
Q3 Income from Operations
-$7.70 mln
Q3 Operating Expenses
$9.87 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $13.50, about 64.4% above its November 11 closing price of $4.81

Press Release: ID:nGNX22bb3K

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)